Cablivi for Acquired Thrombotic Thrombocytopenic purpura

February 18, 2019

What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.

Cablivi (caplacizumab-yhdp, Sanofi Genzyme)

Indications: Treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy

Dosage:

  • Day 1 of treatment: 11-mg bolus intravenous injection at least 15 min prior to plasma exchange, followed by 11-mg subcutaneous injection after plasma exchange

  • 11-mg subcutaneous injection once daily for 30 days following plasma exchange 

  • Treatment may be extended for a maximun of 28 days only if persistent underlying diseases remain present

  • Discontinue if two or more recurrences of aTTP occur while on Cablivi 

Contraindications: Previous severe hypersensitivity reaction to caplacizumab-yhdp or any of the excipients. 

 

Click here for more prescribing information